Dren Bio Announces $65 Million Series B Financing To Advance Its Lead Asset Into The Clinic And To Accelerate Development Of New Product Candidates From Its Targeted Myeloid Engager And Phagocytosis Platform

Dren Bio, Inc. (“Dren Bio” or the “Company”) today announced the completion of their $65 million Series B financing, pushing the Company’s total capital received to date over $156 million. Following the financing, Dren Bio is well-capitalized to reach multiple key inflection points across both its drug discovery programs over the coming years.